Oral antihyperglycemic agents and renal disease: New agents, new concepts

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Yale, Jean François ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG METABOLISM; EDEMA; FLATULENCE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER DYSFUNCTION; NAUSEA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETINOPATHY; SIDE EFFECT; WEIGHT GAIN; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 20844435106     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110974     Document Type: Conference Paper

References (20)

1. Gerstein HC: Dysglycaemia: A cardiovascular risk factor. Diabetes Res Clin Pract 97 40[Suppl]: S9-S14, 1998
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
3. Stratton IM, Adler AI, Neil AW, UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321: 405-412, 2000
4. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 27[Suppl 2], 2003
6. Bogardus C, Ravussin E, Robbins DC, Wolfe RR, Horton ES, Sims EA: Effects of physical training and diet therapy on carbohydrate metabolism in patients with glucose intolerance and non-insulin-dependent diabetes mellitus. Diabetes 33: 311-318, 1984
7. UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for 3 years. BMJ 310: 83-88, 1995
8. DeFronzo RA, Goodman AM, and the Multicentre Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541-549, 1995
9. Garber A, Duncan T, Goodman A, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: Results of a double-blind, placebo controlled, dose-response trial. Am J Med 103: 491-497, 1997
10. Goldberg, Einhorn D, Lucas C, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG: A randomized, placebo controlled trial of repaglinide in the treatment of type II diabetes. Diabetes Care 21: 1897-1903, 1998
11. Jovanovic L, Dailey G 3rd, Huang WC, Strange P, Goldstein BJ: Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 40: 49-57, 2000
12. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928-935, 1994
13. Rodger N, Chiasson JL, Josse R, Hunt JA, Palmason C, Ross SA, Ryan EA, Tan MH, Wolever TM: Clinical experience with acarbose: Results of a Canadian multicentre study. Clin Invest Med 18: 318-324, 1995
14. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T: European study on dose-response relationship on acarbose as a first-line drug in insulin-dependent diabetes mellitus: Efficacy and safety of low and high doses. Acta Diabetol 35: 34-40, 1998
15. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D; Glyburide/Metformin Initial Therapy Study Group: Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 4: 201-208, 2002
16. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27: 256-263, 2004
17. Gan SC, Barr J, Arieff AI, Pearl RG: Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 152: 2333-2336, 1992
18. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI: Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43: 252-259, 2003
19. Krepinsky J, Ingram AJ, Clase CM: Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35: 500-505, 2000
20. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C: Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57: 147-152, 2001